La vendita allo scoperto per Forward Pharma A/S ADR dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Forward Pharma A/S ADR. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Forward Pharma A/S ADR (OTC:FWPAY) Azioni, Report sulle vendite allo scoperto

Forward Pharma A/S ADR

October retail sales in the United States grew more than expected and their annual growth recorded the highest pace since July 2024, suggesting that U.S. consumers showed continued resilience in their spending habits ahead <a href="https://www.benzinga.com/topic/2024-election">of the presidential elections. </a>
Retail and food services sales reached $718.9 billion in October, marking a 0.4% increase over September. The figure is seasonally adjusted but not adjusted for inflation and is an advance estimate released by a government agency Friday. 
The monthly growth figure topped market expectations for a 0.3% increase, according to consensus estimates from TradingEconomics, but represented a deceleration from the upwardly revised 0.8% increase recorded in September.
<h3 class="wp-block-heading">Electronics Shopping Rebounds In October</h3>
On a year-over-year basis, retail sales grew by a robust 2.8%, the highest in three months and the second-strongest since April, up from the upwardly revised 2% in September. 
Excluding motor vehicles and parts, retail sales rose by just 0.1% month-over-month, down from the upwardly revised 1% growth in September, missing expectations of 0.3%. When stripping out gasoline, motor vehicles, and parts, sales inched 0.1% up in October, a noticeable deceleration from the 1.2% growth seen the previous month.
Within spending categories, electronic and appliance stores recorded the largest monthly gain, with sales increasing 2.3%, rebounding significantly from the 2.9% decline in September. 
Motor vehicle and parts dealers saw a 1.6% rise, accelerating from the previous 0.2% growth. 
On the other hand, miscellaneous store retailers registered the steepest monthly decline, with sales contracting 1.6%, followed closely by furniture and home furniture stores, which saw sales fall 1.3%.
Before the report's release, traders were pricing in a 58% probability of a 25-basis-point rate cut at the Federal Reserve's December meeting, according to the CME FedWatch Tool. 
Those expectations shifted substantially downward from about 80% after Fed Chair Jerome Powell stated on Thursday that the Federal Reserve is not in a hurry<a href="https://www.benzinga.com/news/econ-s/24/11/41991849/powell-with-strong-us-economy-fed-has-no-need-to-be-in-a-hurry-to-lower-rates"> to lower interest rates. </a>
Powell also emphasized that the strength of the U.S. economy allows policymakers to approach rate decisions carefully, suggesting the potential for a pause in rate cuts.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/treasuries/24/11/41993899/powells-hawkish-remarks-shake-markets-stocks-fall-dollar-rockets-bitcoin-dips">Powell&#8217;s Hawkish Remarks Shake Markets: Stocks Fall, Dollar Rockets, Bitcoin Dips</a></li>
</ul>
Photo via Shutterstock.

Retail Sales

Econ #s

Economics

October Retail Sales Top Expectations As US Consumers Increase Tech Spending

On Friday, the FDA accepted for review the resubmission of the supplemental biologics license application (sBLA) for Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent (dupilumab) for patients ages 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 <a href="https://www.benzinga.com/pressreleases/24/11/g42000231/press-release-dupixent-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-spontaneous-urtic" target="_blank" rel="noreferrer noopener">antihistamine treatment</a>.
The target action date for the FDA decision is April 18, 2025.
Data from the multi-study LIBERTY-CUPID phase 3 clinical program (<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2021/2021-07-29-05-00-00-2270858" rel="noreferrer noopener">Study A</a>,&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-18-06-00-00-2387700" rel="noreferrer noopener">Study B</a>, and&nbsp;<a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-05-00-2944239" rel="noreferrer noopener">Study C</a>) for Dupixent in CSU support the resubmitted supplemental marketing.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41945225/regeneron-sanofis-dupixent-approval-signals-major-treatment-breakthrough-for-smokers-lung-disease" rel="noreferrer noopener">Regeneron/Sanofi&#8217;s Dupixent Approval Signals Major Treatment Breakthrough For Smokers&#8217; Lung Disease</a>
Earlier this year, Japan was the first country in the world to&nbsp;approve&nbsp;and launch Dupixent for adult and adolescent CSU patients based on the results <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40814475/sanofi-regeneron-drug-dupixent-shows-successful-treatment-of-patients-with-inflammatory-skin-dise" rel="noreferrer noopener">from Study A</a>.
The supplemental marketing adds results from Study C, conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY-CUPID pivotal study in biologic-naïve patients, met its primary and key secondary endpoints, confirming the results of the previous Study A.
Results showed that Dupixent significantly reduced itch and urticaria activity (itch and hives).
In March 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-03-07-06-00-00-2621670" rel="noreferrer noopener">accepted</a> the supplemental marketing application for Dupixent&nbsp;(dupilumab) to treat adults and adolescents with chronic spontaneous urticaria, with the target action date for the FDA decision of October 22, 2023.
In October 2023, the FDA <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-20-21-00-00-2764252" rel="noreferrer noopener">issued</a> a Complete Response Letter for the supplemental Biologics License Application and stated that additional efficacy data are required to support approval.
It did not identify any issues with safety or manufacturing.
CSU is a chronic inflammatory skin disease driven partly by type-2 inflammation, which causes sudden hives and recurring itch.
CSU is typically treated with H1 antihistamines, medicines that target H1 receptors on cells to control urticaria symptoms.
More than 300,000 people in the US suffer from CSU that is inadequately controlled by antihistamines.
Price Action: REGN stock closed at $782.51 on Thursday, and SNY stock is up 1.09% at $48.34 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" target="_blank" rel="noreferrer noopener">UnitedHealth&#8217;s Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

News

Health Care

General

REGN

FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease

WIIM

OneStream shares are trading lower after the company announced a 15 million class A common stock secondary offering.

InMed Pharmaceuticals shares are trading lower after the company reported a year-over-year decrease in Q4 EPS results.

Earnings

Know Labs FY24 EPS  $(0.20) vs $(0.41) YoY

Company's Rapid Alcohol-Reducing Beverage, Sure Shot, to be Sold in 192 Stores Across Nevada, Arizona, and California
JUPITER, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new agreement with a leading national grocery chain to sell its convenient, newly branded 4 oz. Sure Shot beverages in select stores across the Southwest. This chain boasts over 2,200 stores nationwide, making them a significant player in the grocery industry.
This strategic launch in 192 stores across Nevada, Arizona, and California represents a significant milestone in Safety Shot's growth strategy. It provides access to a substantial and rapidly growing alcohol beverage market and marks a key step towards the Company's goal of nationwide distribution.

SHOT

Safety Shot Announced A New Agreement With A Leading National Grocery Chain To Sell Its Convenient, Newly Branded 4 Oz. Sure Shot Beverages In Select Stores Across The Southwest

Evercore ISI Group analyst Duane Pfenningwerth downgrades Diamondrock Hospitality (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) from Outperform to In-Line and maintains the price target from $10.5 to $10.5.

Downgrades

Price Target

Analyst Ratings

Evercore ISI Group Downgrades Diamondrock Hospitality to In-Line, Maintains Price Target to $10.5

RVYL

Ryvyl shares are trading lower. HC Wainwright & Co. reiterated a Neutral rating on the stock.

<a href="https://www.globenewswire.com/Tracker?data=oitox4x61cysgmwWmH-4y0XEjZKDx7vc9SYpYpngH33pFS6I3IlY-q-LsjR9lIzyVSYOkq29dQRMXutaPBuvrmxtA0l3Px7d-VkLvq27Yf5vY5uqf3Do5mhfCjwAUgGo">SeaStar Medical Holding Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, has begun shipping QUELIMMUNE&#x2122; to a third hospital customer. QUELIMMUNE is the Company's Selective Cytopheretic Device (SCD) for treating critically ill children in the intensive care unit (ICU) with acute kidney injury (AKI) and sepsis.

SeaStar Medical Reaches Milestone Of 100th QUELIMMUNE Commercial Device As Shipments Begin To Its Third Hospital Customer

Lument Finance Trust shares are trading higher following a Q3 earnings beat.

SPPL

SIMPPLE shares are trading higher after the company announced a $400,000 contract to supply autonomous cleaning robots at Singapore's International Airport Terminal.

SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) reported quarterly losses of $(0.25) per share. This is a 74.75 percent increase over losses of $(0.99) per share from the same period last year. The company reported $881.69 thousand in sales this quarter. This is a 34.66 percent decrease over sales of $1.35 million the same period last year.

SBET

SharpLink Gaming Q3 EPS $(0.25) Up From $(0.99) YoY, Sales $881.69K Down From $1.35M YoY

LIFW

MSP Recovery shares are trading lower. The company reported Q3 financial results.

BTOC

Armlogi Q1 Total Revenue $42.5M, Up 3% YoY; EPS $(0.11) vs $0.07 YoY

SharpLink Gaming Q3 Revenue $881.690K Down From $1.349M YoY

SIMPPLE Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) ("SIMPPLE" or "the Company"), a leading technology provider and innovator in the facilities management (FM) sector, today announced that the Company has been awarded a $400,000 contract for the supply of autonomous cleaning robotics at one of Singapore's international airport terminals.
This robot tender success comes as part of the airport's renewal program and complements the existing fleet of autonomous cleaning robots across its airport terminals, where the Company has been one of two incumbent robotic suppliers for the past five years.
The results of the ongoing tender exercise for the remaining airport terminals will be announced in the near future, with an expected aggregate contract value of $1.8 million.

Contracts

Global

SIMPPLE Wins $400,000 Contract To Supply Autonomous Cleaning Robots At Singapore's International Airport Terminal; The Results Of The Ongoing Tender Exercise For The Remaining Airport Terminals Will Be Announced In The Near Future, With An Expected Aggregate Contract Value Of $1.8M

PHIO

Phio Pharma shares are trading higher. The company reported Q3 financial results.

EHang Holdings Limited ("EHang" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), the world's leading Urban Air Mobility ("UAM") technology platform company, today announced that it has signed a cooperation framework agreement ("Agreement") with Zhejiang Sunriver Culture and Tourism Co., Ltd. ("Sunriver", 600576.SH), a China A-share listed company, to explore an industrial model that integrates low-altitude economy with cultural tourism in China. Under the Agreement, Sunriver plans to purchase 50 units of EH216-S or similar pilotless passenger-carrying aircraft from EHang for its cultural tourism projects based on market development needs. Sunriver has placed a purchase order for 5 units of EH216-S as the first batch for aerial tourism use cases. The remaining aircraft will be gradually deployed in the tourism attractions under the Sunriver.

EHang Partners with Sunriver To Expand Chinese Cultural Tourism Market With Purchase Plan For 50 Units Of EH216-S Or Similar Pilotless Passenger-Carrying Aircraft From EHang For Its Cultural Tourism Projects Based On Market Development Needs

Suburban Propane Partners, L.P. (NYSE:<a href="https://www.benzinga.com/stock/SPH#NYSE">SPH</a>), a nationwide distributor of propane, renewable propane, renewable natural gas, fuel oil and related products and services, as well as a marketer of natural gas and electricity and investor in low carbon fuel alternatives, announced today an executive promotion in line with its planned management succession. As previously announced, Steven C. Boyd, the Partnership's Chief Operating Officer, will retire effective January 1, 2025.
The Partnership announced that Alejandro ("Alex") Centeno has been promoted to Senior Vice President – Operations as successor to Mr. Boyd. In his role, Mr.&nbsp;Centeno will report to Michael A. Stivala, President and Chief Executive Officer. Mr.&nbsp;Centeno has been with the Partnership for over 15 years, where he has held several managerial positions within the operations, most recently, rising to the level of Vice President – Operations since August 2023. In his new position, Mr.&nbsp;Centeno will be responsible for leading all aspects of the day-to-day operations of the propane business, as well as advancing the Partnership's customer base growth and retention initiatives, driving continued improvements in operational efficiencies and overseeing operational support functions; including safety, marketing and fleet management.&nbsp;

Management

Suburban Propane Partners, L.P.'s Steven C. Boyd, The Partnership's Chief Operating Officer, Will Retire Effective January 1, 2025; Alejandro ("Alex") Centeno Has Been Promoted To Senior Vice President – Operations As Successor To Mr. Boyd

Benchmark analyst Daniel Kurnos maintains Cineverse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>) with a Speculative Buy and raises the price target from $9 to $10.

CNVS

Benchmark Maintains Speculative Buy on Cineverse, Raises Price Target to $10

Forward Pharma

Comments

Forward Pharma A/S ADR

Vendite allo scoperto

Forward Pharma A/S ADR (OTC:FWPAY) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO